Prostate cancer expectant management

Individuals with T2b and T2c disease or a Gleason score of 7 or a PSA ranging from 10 to 20 ng/mL (10 to 20 mcg/L) are considered at intermediate risk for prostate cancer recurrence.26 Individuals with less than a 10-year expected survival may be offered expectant managment, radiation therapy, or radical prostatectomy, and those with a greater than or equal to 10-year life expectancy may be offered either radical prostatectomy or radiation therapy (Table 89-5). 

Prostate cancer treatment depends on the stage, age, Gleason score, and PSA concentration. Treatment options include expectant management, radiation therapy, radical prostatectomy, hormonal therapy, and chemotherapy. 

Wilt TJ, Brawer MK. Early intervention or expectant management for prostate cancer. The Prostate Cancer Intervention Versus Observation Trial (PIVOT) A randomized trial comparing radical prostatectomy with expectant management for the treatment of clinically localized prostate cancer. Semin Urol 1995 13 130-136. 

---